Table of Contents
1. INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2. RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3. MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4. MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL MATERNAL HEALTH MARKET, BY TYPE OF PREGNANCY
5.1 INTRAUTERINE
5.2 ECTOPIC
5.3 TUBAL
5.4 OTHERS
GLOBAL MATERNAL HEALTH MARKET, BY RISKS IN PREGNANCY
6.1 HIGH
6.2 MOLAR
7 GLOBAL MATERNAL HEALTH MARKET BY, COMPLICATIONS
7.1 MICARRIAGE
7.1.1 THREATENED
7.1.2 INEVITABLE
7.1.3 COMPLETE
7.1.4 INCOMPLETE
7.2 PREMATURE LABOR & BIRTH
7.3 PREECLAMPSIA
7.4 GESTATIONAL DIABETES
7.5 PLCENTA PREVIA
7.6 OTHER
GLOBAL MATERNAL HEALTH MARKET, BY DELIVERY TYPE
8.1 VAGINAL DELIVERY
8.2 CESARIAN SECTION
8.3 VACUUM EXTRACTION
8.4 FORCEPS DELIVERY
GLOBAL MATERNAL HEALTH MARKET, BY CARE
9.1 PRE-NATAL CARE
9.2 POST NATAL CARE
GLOBAL MATERNAL HEALTH MARKET, BY DRUG CLASS
10.1 HORMONES
10.2 NUTRITIVES
10.3 ANALGESICS
10.4 ANTI-INFECTIVES
10.5 OTHERS
11. GLOBAL MATERNAL HEALTH MARKET, BY REGION
11.1 INTRODUCTION
11.1.1 AMERICAS
11.1.1.1 NORTH AMERICA
11.1.1.1.1 US
11.1.1.1.2 CANADA
11.1.1.2 SOUTH AMERICA
11.1.2 EUROPE
11.1.2.1 GERMANY
11.1.2.2 FRANCE
11.1.2.3 UK
11.1.2.4 ITALY
11.1.2.5 SPAIN
11.1.2.6 REST OF EUROPE
11.1.3 ASIA PACIFIC
11.1.3.1 JAPAN
11.1.3.2 CHINA
11.1.3.3 INDIA
11.1.3.4 AUSTRALIA
11.1.3.5 REPUBLIC OF KOREA
11.1.3.6 REST OF ASIA PACIFIC
11.1.4 MIDDLE EAST & AFRICA
11.1.4.1 SAUDI ARABIA
11.1.4.2 UAE
11.1.4.3 EGYPT
11.1.4.4 SOUTH AFRICA
11.1.4.5 REST OF MIDDLE EAST & AFRICA
12. COMPETITIVE LANDSCAPE
12.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
12.1.1 STRATEGIC PARTNERSHIP
12.1.2 MERGER & ACQUISITION
13. COMPANY PROFILE
13.1 AGEIL THERAPEUTICS
13.1.1 OVERVIEW
13.1.2 PRODUCT OVERVIEW
13.1.3 FINANCIALS
13.1.4 KEY DEVELOPMENTS
13.2 FUJI LATEX Co
13.2.1 OVERVIEW
13.2.2 PRODUCT OVERVIEW
13.2.3 FINANCIALS
13.2.4 KEY DEVELOPMENTS
13.3 JOHNSON & JOHNSON
13.3.1 OVERVIEW
13.3.2 PRODUCT OVERVIEW
13.3.3 FINANCIALS
13.3.4 KEY DEVELOPMENT
13.4 OKAMOTO INDUSTRIES
13.4.1 OVERVIEW
13.4.2 PRODUCT OVERVIEW
13.4.3 FINANCIALS
13.4.4 KEY DEVELOPMENTS
13.5 RECKITT BENCKISER GROUP PLC.
13.5.1 OVERVIEW
13.5.2 PRODUCT OVERVIEW
13.5.3 FINANCIALS
13.5.4 KEY DEVELOPMENTS
13.6 SANOFI
13.6.1 OVERVIEW
13.6.2 PRODUCT OVERVIEW
13.6.3 FINANCIALS
13.6.4 KEY DEVELOPMENTS
13.7 OTHERS
CONCLUSION
14.1 KEY FINDINGS
14.1.1 FROM CEO’S VIEWPOINT
14.1.2 UNMET NEEDS OF THE MARKET
14.2 KEY COMPANIES TO WATCH
14.3 PREDICTION OF MATERNAL HEALTH INDUSTRY
15. APPENDIX